CHARLOTTE, N.C., May 5, 2016 /PRNewswire/ -- SonaCare
Medical, the leading developer and manufacturer of High Intensity
Focused Ultrasound (HIFU) Technologies, announces today a marketing
alliance with Invivo, a business of Royal
Philips (NYSE: PHG; AEX: PHIA) with over 20-years of history
as the pioneer of progressive MRI coils, advanced clinical
visualization systems, and MRI-compatible interventional
devices.
As part of this strategic partnership, SonaCare Medical has
licensed from Invivo their UroNav® fusion software, which engineers
from both companies have collaborated on to achieve compatibility
with the Sonablate® planning system. This creates a seamless
process whereby urologists, who have used UroNav to annotate and
biopsy targeted prostate tissue, can now easily localize the
specific tissue appropriate for ablation directly in the Sonablate
software. In addition, SonaCare and Invivo have created a selling
relationship that will allow Invivo's extensive network of sales
specialists to sell Sonablate directly to almost 200 U.S.-based
UroNav facilities.
"This is a major strategic partnership for SonaCare,"
comments Dr. Mark Carol, CEO of
SonaCare Medical. "Working together, Invivo and SonaCare are
putting in place a broad product portfolio for performing advanced
diagnostics, targeted ablation, and systematic patient follow up,
as well as a means for delivering that platform to the market.
These are very exciting times for both of our organizations and for
the physicians and patients they serve around the world."
"We're excited about this new alliance with SonaCare and the
value this will bring to our mutual customers," said
Thomas Tynes, Senior Director,
Strategy & Business Development at Invivo Corporation.
"Achieving compatibility between our respective products
provides Sonablate customers with much easier access to Invivo's
integrated portfolio of Prostate Oncology Solutions, including our
market-leading UroNav® Fusion Biopsy System. We look forward to
working together with SonaCare to provide our customers and their
patients with innovative clinical solutions throughout the care
continuum."
The UroNav-Sonablate software package will be available for
viewing this week at both the SonaCare Medical booth (#4547) and
the Invivo booth (#5333) at the Annual meeting of the American
Urological Association (AUA) in San
Diego May 7th – May 10th.
Sonablate® is the first device to receive regulatory
authorization from the FDA for the focused ultrasound ablation of
prostate tissue. Since its introduction over 15 years ago,
Sonablate® technology has been used around the world on 15,000
patients in over 30 countries, including approximately 4,000 U.S.
men who have had this procedure performed outside the U.S.
About SonaCare Medical, LLC
SonaCare Medical is a
world leader in minimally invasive focused ultrasound (HIFU)
technologies. SonaCare Medical is committed to developing focused
ultrasound related technologies that support precise and innovative
procedures for the treatment of a range of medical conditions.
SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs
and manufactures medical devices, including the following:
Sonablate®, which has 510(K) clearance in the U.S. under a De Novo
regulatory classification; Sonablate® 500, which has CE Marking and
has obtained regulatory authorization in more than 49 countries
outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation
system, which has 510(K) clearance in the U.S., has CE Marking and
has obtained regulatory authorization in more than 30 countries
outside the U.S.
For additional information, visit www.SonaCareMedical.com
Forward Looking Statements.
The Company's forward-looking statements are based on
management's current expectations and assumptions regarding the
Company's business and performance, the economy and other future
conditions and forecasts of future events, circumstances and
results. As with any projection or forecast, forward-looking
statements are inherently susceptible to uncertainty and changes in
circumstances. The Company's actual results may vary materially
from those expressed or implied in its forward-looking statements.
Any forward-looking statement made by the Company speaks only as of
the date on which it is made. The Company is under no obligation
to, and expressly disclaims any obligation to, update or alter its
forward-looking statements, whether as a result of new information,
subsequent events or other factors.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sonacare-medical-and-invivo-join-forces-to-help-physicians-better-locate-and-track-appropriate-targets-for-prostate-hifu-ablation-300263400.html
SOURCE SonaCare Medical